LungenClinic Grosshansdorf GmbH
- Address
- lock Available on a paid plan
Analytical, Diagnostic, Therapeutic Techniques and Equipment
The site focuses on developing and validating advanced diagnostic tools and therapeutic devices for lung diseases.
- Development of imaging biomarkers for early detection of lung cancer
- Evaluation of minimally invasive bronchoscopy technologies
- Assessment of novel pulmonary function testing platforms
Research aims to improve early diagnosis and optimize treatment delivery for patients with non‑small cell lung cancer and other respiratory conditions.
E‑Surgical Procedures, Operative [E04]
Trials investigate innovative surgical and endoscopic procedures for resectable lung tumors.
- Video‑assisted thoracoscopic surgery (VATS) for stage I–II NSCLC
- Robotic‑assisted lobectomy outcomes
- Peri‑operative imaging guidance to reduce margins
The goal is to enhance surgical precision and reduce postoperative complications in patients undergoing curative resection of lung cancer.
Diseases [C] - Hemic and Lymphatic Diseases [C15]
The clinic examines lymphatic involvement in thoracic malignancies to improve staging and treatment planning.
- Study of mediastinal lymph node staging accuracy
- Impact of lymphatic drainage patterns on metastatic spread
- Biomarker profiling of lymphatic endothelial cells in cancer
Efforts aim to refine staging and guide adjuvant therapy decisions for advanced NSCLC.
Diseases [C] - Neoplasms [C04]
The core research portfolio targets a broad spectrum of thoracic cancers, especially multiple subtypes of lung cancer.
- ALK‑positive and RET‑fusion positive NSCLC targeted therapy trials
- KRAS G12C mutant lung cancer investigational agents
- Small‑cell lung cancer immunotherapy combinations
- Adjuvant strategies for resected non‑squamous NSCLC
Studies are designed to test new systemic treatments, improve survival, and personalize therapy based on molecular profiling of neoplasms.
Diseases [C] - Nutritional and Metabolic Diseases [C18]
Research includes metabolic complications associated with cancer and chronic lung disease.
- Cachexia management in advanced lung cancer
- Metabolic profiling of patients receiving targeted therapies
- Nutrition‑support interventions during chemoradiation
The aim is to mitigate weight loss and improve quality of life for patients with cancer‑associated cachexia and metabolic disturbances.
Diseases [C] - Respiratory Tract Diseases [C08]
The largest focus area, covering both malignant and non‑malignant lung conditions.
- Chronic obstructive pulmonary disease (COPD) exacerbation reduction trials
- Progressive pulmonary fibrosis treatment studies
- Early‑stage NSCLC screening and treatment pathways
- Large‑cell neuroendocrine carcinoma therapeutic evaluation
Objectives range from preventing disease progression to testing novel agents that extend survival for patients with respiratory tract diseases.
Health Care [N] - Environment and Public Health [N06]
The clinic participates in public‑health initiatives linked to lung disease risk and prevention.
- Air‑quality monitoring impact on COPD incidence
- Smoking‑cessation program effectiveness
- Population‑based lung cancer screening feasibility
These projects aim to reduce environmental risk factors and promote early detection to lower the burden of lung disease in the community.
Psychiatry and Psychology [F] - Behavioral Disciplines and Activities [F04]
Recognizing psychosocial aspects, trials address mental health and behavior in patients undergoing lung cancer treatment.
- Psychological support interventions during chemoradiation
- Assessment of anxiety and depression in COPD patients
- Behavioral strategies to improve medication adherence
Research seeks to enhance patient resilience and treatment adherence, ultimately improving outcomes for those with lung cancer and chronic respiratory illnesses.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 7 therapeutic areas and 15 of 99 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 98 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 17 by active trials.
- 1Merck Sharp & Dohme LLC4active
lock +16 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB9trials
lock +13 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in LungenClinic Grosshansdorf GmbH
lock Showing 1 of 65 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab | Merck Sharp & Dohme LLC | Phase III | Recruiting | Aug 2018 | — |
IMP list
lock Showing 1 of 99 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Carboplatin | 31 | Unknown | 2017-09-18 | 2026-06-23 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.